Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,357 other S bills in the 117th — cohort avg 38d
Streamlining EIDL Act This bill requires the Small Business Administration (SBA) to provide status updates on, review, and approve or disapprove Economic Injury Disaster Loans within certain time frames. It also requires the SBA to report on its efforts to address fraud under the program.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (1)
2026 · third_quarter · Medicare/Medicaid
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment S.3345, PBM Price Transparency and Accountability Act HR 6166, Lowering Drug Costs for American Families Act S 3019 - No Big Blockbuster Bailouts Act S 3349 PBM Disclosure Act HR 4317 PBM Reform Act Issues related to Public law 117-1769 Inflation Reduction Act HR 1672 Maintaining Investments in New Innovation Act (MINI) HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 PL 119-75 Consolidated Appropriations Act of 2026 HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act HR 10628/ S 5571 Biosimilars Access and Affordability Act S 5244 Sustain 340B Act HR 9599 Secure 340B Act
Read twice and referred to the Committee on Small Business and Entrepreneurship.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $3,150,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · second_quarter · Medicare/Medicaid
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment S.3345, PBM Price Transparency and Accountability Act HR 6166, Lowering Drug Costs for American Families Act S 3019 - No Big Blockbuster Bailouts Act S 3349 PBM Disclosure Act HR 4317 PBM Reform Act Issues related to Public law 117-1769 Inflation Reduction Act HR 1672 Maintaining Investments in New Innovation Act (MINI) HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 PL 119-75 Consolidated Appropriations Act of 2026 HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act
Client expense: $2,440,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · first_quarter · Medicare/Medicaid
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S.3345, PBM Price Transparency and Accountability Act HR 6166, Lowering Drug Costs for American Families Act S 3019 - No Big Blockbuster Bailouts Act S 3349 PBM Disclosure Act HR 4317 PBM Reform Act Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act (EPIC) HR 1672 Maintaining Investments in New Innovation Act (MINI) HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 PL 119-75 Consolidated Appropriations Act of 2026
Client expense: $2,580,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2025 · fourth_quarter · Medicare/Medicaid
Issues related to drug pricing Issues related to Public law 117-1769 Inflation Reduction Act Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment HR 946 Optimizing Research Progress Hope and New Cures Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025 S.3345, PBM Price Transparency and Accountability Act H.R. 6166, Lowering Drug Costs for American Families Act S.3019 - No Big Blockbuster Bailouts Act H.Res. 928 - Affirming support for most-favored-Nation drug pricing for United States patients S 3349 PBM Disclosure Act HR 4317 PBM Reform Act
Client expense: $3,550,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2025 · fourth_quarter · Health Issues
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. HR 946 Optimizing Research Progress Hope and New Cures Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act HR 5526 Biosimilar Red Tape Elimination Act HR 2214 DRUG Act H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025 HR 5509 Safe Step act HR 5256 340B Access Act HR 4581 340B Patients Act S2296 NDAA FY2026 National Defense Authorization Act, issued related to Biosecure Act H.R. 6703 Lower Health Care Premiums for All Americans Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act H.Res. 928 Affirming support for most-favored-Nation drug pricing for United States patients S 3349 PBM Disclosure Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act
Client expense: $3,550,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
| Democratic |
| CO |
| Mike Crapo | Republican | ID |
| Raphael G. Warnock | Democratic | GA |
| Roger Marshall | Republican | KS |
| Tim Scott | Republican | SC |